US 12,123,060 B2
Method for identifying targets for precision cancer therapy
George Steven Bova, Tampere University (FI); and Matti Nykter, Tampere University (FI)
Assigned to Tampere University Foundation sr, Tampere University (FI)
Filed by Tampere University Foundation sr, Tampere University (FI)
Filed on Oct. 6, 2021, as Appl. No. 17/495,468.
Prior Publication US 2023/0104563 A1, Apr. 6, 2023
Int. Cl. C12Q 1/6886 (2018.01)
CPC C12Q 1/6886 (2013.01) [C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01)] 14 Claims
 
1. A method of identifying a molecular target for precision cancer therapy in a patient in need thereof, the method comprising:
a) determining truncal clonal and subclonal cancer cell composition of a first sample obtained from the patient before an initial cancer treatment or treatment interval;
b) determining truncal clonal and subclonal cancer cell composition of a second sample obtained from the patient after the initial cancer treatment or treatment interval;
c) comparing the truncal and subclonal cancer cell compositions of the first and the second samples to distinguish a cancer cell subclone eradicated by the cancer treatment or treatment interval and a cancer cell subclone resistant to the cancer treatment or treatment interval;
d) based on a comparison of molecular characteristics of the eradicated cancer cell subclone and the resistant cancer cell subclone, to identifying one or more molecular features of the eradicated cancer cell subclone that indicate one or more of FANCI, FANCD2, or EYA4 as one or more molecular targets for precision cancer therapy directed to converting the resistant cancer cell subclone to an eradicable cancer cell subclone; and
e) administering the precision cancer therapy as a subsequent cancer treatment or treatment interval, after the initial cancer treatment or interval, to the patient, wherein the precision cancer therapy converts the resistant cancer cell subclone to an eradicable cancer cell subclone in the patient.